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Abstract
BACKGROUND: Breast cancer is the most common cancer in Pakistani women. We report the presenting features, treatment patterns and 
survival of breast cancer from a University Hospital in Southern Pakistan and compare the data with international population based studies. 
MATERIALS AND METHODS: Medical records of patients diagnosed to have breast cancer between January 1999 and November 2008 were 
reviewed retrospectively. RESULTS: A total of 845 patients were identified. Median age of diagnosis was 48 years (range 18‑92). Clinical stage was 
as follows: Stage I 9.9%; Stage II 48.5%; Stage III 26.2%; Stage IV 13.8%; data not available 1.5%. Approximately, half (51.6%) were estrogen 
receptor (ER) positive and 17.5% over‑expressed Her2/neu. Nearly 23% patients received neo‑adjuvant chemotherapy while 68.9% received 
adjuvant chemotherapy. Anthracycline based treatment was the most common treatment until 2003 while later on, patients also received taxanes 
and trastuzumab based therapy. Age, stage, tumor size, lymph node status, tumor grade, ER status, treatment with hormonal therapy and radiation 
were the major predictive factors for overall survival (OS). We report an impressive 5 year OS of 75%, stage specific survival was 100%, 88% 
and 58% for Stages I, II and III respectively.  CONCLUSION: The majority of patients present at a younger age and with locally advanced disease. 
However, short term follow‑up reveals that the outcomes are comparable with the published literature from developed countries. Long‑term follow‑up 
and inclusion of data from population‑based registries are required for accurate comparison.
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Introduction
Breast cancer remains the leading cause of cancer diagnosis 
and cancer-related death in women, world-wide. Mortality 
from breast cancer in the western hemisphere has recently 
showed a trend of decline, understandably this being a 
result attributable to effective screening and early detection 
programs, health awareness, access to health-care and a 
better health-care infrastructure. Developing world has on 
the other hand shown an increasing mortality, perhaps as 
a result of lack of availability of factors mentioned for the 
west, as well increasing “westernization” of the life-style.[1] 
De novo geographical factors are also considered to be an 
important contributor for outcomes from breast cancer.
The incidence of breast cancer varies almost 10 fold if data 
were compared from different countries.[2] Comparison of 
breast cancer data from various geographic locations is also 
considered to be important to understand underlying causes 
of disease or the reasons of death.[3]
Pakistan is a developing country, where health-care access 
is limited and fragmented. Population based registries 
report the age-standardized incidence of 9.1/100,000 
for breast cancer, which is the highest reported from 
the area and is considerably higher than the much more 
populous neighboring India.[4] The Aga Khan university 
Hospital is the largest private medical hospital, in the 
country and is located in the city of Karachi in Southern 
Pakistan. It receives patients from all over the country.[4] The 
comprehensive cancer care services make it a reliable cancer 
care center in the country.[5]
This report covers different aspects of breast cancer 
observed at our institution, from demographic features, 
histopathological subtypes, treatment modalities, patterns 
and incidence of relapse and the treatment strategies in the 
metastatic setting, as well as the survival.
Materils and Methods
Data were analyzed retrospectively. The diagnoses are stored 
electronically using international classification of diseases 
version 9/10. Clinical data on consecutive patients admitted 
to the hospital between January 1999 and November 
2008 and diagnosed to have invasive breast cancer were 
retrieved. Patients who were diagnosed with the disease 
earlier, but experienced relapse during the study period 
were also included. The hospital is one of the few hospitals 
providing comprehensive cancer care (surgery, chemotherapy, 
radiotherapy, palliative care, screening and molecular testing) 
in Pakistan. Majority of the patients included were diagnosed 
and treated at our hospital. For patients who had been 
initially diagnosed elsewhere, all specimens were reviewed 
by the pathology department for verification of diagnosis, 
immunohistochemistry (IHC) for estrogen receptor (ER), 
progesterone (PR) and Her2/neu status or fluorescence 
in situ hybridization (FISH) for Her2/neu gene, where 
indicated.
The medical records of all patients with a diagnosis of 
invasive breast cancer were reviewed and information 
was extracted on to a pre-designed database. Variables 
included age, gender, date of diagnosis, side of involvement; 
histopathological type of tumor; tumor size (clinical and 
pathological), lymph node involvement; number of lymph 
nodes removed, tumor grade, lymphovascular invasion, 
ER status, PR status, and Her2/neu status. Clinical and 
pathological stages were determined using the 6th edition of 
American Joint Committee on Cancer (AJCC) manual. The 
date of last follow-up exam, date and site of relapse and date 
of death, when relevant were also recorded. The relapses 
were confirmed from the hospital records and during patient 
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follow-up in clinics (not described for patients who lost to 
follow-up) and death was also confirmed either form the 
hospital records or through phone calls.
The data were censored at the date of last follow-up 
exam for each patient and relapse-free survival (RFS) 
was calculated from the date of diagnosis to the date of 
documented relapse. Overall survival (OS) was calculated 
from the date of diagnosis to the date of death or last 
follow-up/death where relevant. OS and RFS were 
determined using the method of Kaplan and Meir; Cox 
proportional hazard model was used to compare the survival 
between different stages. Univariate analysis was performed 
using the Chi-square test. The Cox model was used for 
multivariate analysis including all statistically significant 
factors on univariate analysis. Data were analyzed on 
statistical software package Statistical Package for the Social 
Sciences (version 16.0.2, SPSS, Chicago, IL, USA).
Results
Clinical features
A total of 845 patients were included diagnosed to 
have breast cancer in the study period while remaining 
10 patients were diagnosed earlier, but included in the 
study as they received treatment for disease relapse. All 
but two were females; the median age at the diagnosis 
was 48 years (range 18-92 years). The majority of patients 
were between the ages 40 and 60 years (n = 515, 60.9%), 
15% had a family history of breast cancer, 45.7% of 
all patients were pre-menopausal while remaining had 
achieved menopause prior to diagnosis. Almost half of the 
patients (50.5%) had left-sided breast cancer [Table 1].
Pathological features
Clinical and pathological stages are summarized in Table 2. 
Merely 9.9% patients presented with clinical Stage I 
disease (according to AJCC manual, 6th edition), clinically, 
T4 disease was detected in 21.1% patients; only 12.1% 
of patients presented with clinical T1 lesion at the time of 
diagnosis. Likewise, 43.5% patients had clinically palpable 
nodes. Pathologically mean tumor size was 4.11 cm [Table 2]. 
Microscopically, 42.1% patients had involved lymph nodes, 
the mean number of involved nodes was 6 (range 0-33). 
More than 93% of the patients had infiltrating ductal 
carcinoma as the pathological diagnosis, while infiltrative 
lobular carcinoma (2.7%) was the next common type. Almost 
a quarter (25.9%) of patients had poorly differentiated cancer 
and lymphovascular invasion was seen in 15.1% specimens.
ER status was expressed by 51.6% tumors, whereas, PR was 
expressed by 44%. Data on HER-2/neu status was available 
for 488 (57.7%) patients; 13.1% patients expressed the 
protein using the IHC method, whereas, for another (4.5%) 
patients the gene could be detected using FISH, leading to 
an overall expression rate of 17.6%. Triple negative disease 
was diagnosed for 130 (15.3%) patients [Table 3].
For patients presenting with Stage IV disease at 
presentation (n = 117, 13.8%), bone was the most 
common site of distant disease (n = 74, 63.2%), followed 
by lungs (n = 40, 34.1%); more than one organ was 
involved in 34 patients (29.0%).
Treatment
Of all patients with localized or locally advanced disease at 
presentation (n = 728, 86.2%), 502 (68.9%) were treated 
with adjuvant chemotherapy. For patients who presented 
with metastatic disease (n = 117, 14.1%), palliative 
chemotherapy or hormonal therapy was administered to 
95 (81.2%) patients, 37 patients declined chemotherapy 
while four patients moved from the hospital before the 
initiation of treatment.
Out of 728 patients with non-metastatic disease on 
presentation, 265 (36.4%) patients had locally advanced 
disease (cT3 or positive nodes clinically) and 195 (73.5%) 
of these were treated with neo-adjuvant chemotherapy.
Table 1: Clinical features of all patients treated 
during January 1999 to November 2008
Clinical characteristics Number (%)
Gender
Female 843 (99.8)
Male 2 (0.2)
Age
<40 178 (21.1)
46-60 515 (60.9)
>60 152 (18)
Menopausal status
Pre-menopausal 386 (45.7)
Menopausal 459 (54.3)
Involved side
Left 427 (50.5)
Right 393 (46.5)
Bilateral 25 (3)
Table 2: Clinical and pathological stage of all 
patients
Disease/tumor 
charechtarestic
Clinical 
stage n (%)
Pathological 
stage n (%)
Primary tumor
Tis - 1 (0.1)
T0 - 26 (3.1)
T1 102 (12.1) 178 (21.1)
T2 360 (42.6) 374 (44.3)
T3 173 (20.5) 93 (11.0)
T4 185 (21.9) 67 (7.9)
NA* 25 (3) 106 (12.6)
Node status
N0 441 (52.2) 365 (43.2)
N1 274 (32.4) 178 (21.1)
N2 86 (10.2) 97 (11.5)
N3 8 (0.9) 80 (9.5)
NA* 36 (4.3) 125 (14.8)
Overall stage
0 - 23 (2.8)
I 84 (9.9) 110 (13.0)
II 410 (48.5) 355 (42.0)
III 221 (26.2) 215 (25.4)
IV 119 (14.1) -
NA* 11 (1.3) 27 (3.2)
*Data missing or not applicable
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Almost 2/3 of patients (61.9%) had modified radical 
mastectomy (MRM), while breast conservation surgery was 
performed in 21.2% and 5.1% were treated with simple 
mastectomy because of symptomatic advanced disease. Of 
179 patients who had breast conservation surgery only 
34 patients were administered neo-adjuvant chemotherapy, 
while out of 523 patients who had MRM 130 were treated 
with neo-adjuvant chemotherapy.
Majority of patients were treated with anthracycline based 
regimen (n = 500, 59.1%) while 203 (24.0%) received a 
taxane in addition to other cytotoxics. Amongst 149 patients 
expressing Her2/neu (by IHC or FISH), only 41 patients 
received trastuzumab [Table 4]. Only 24 patients completed 
one calendar year of treatment. Most declined and discontinued 
the treatment per cost of therapy. A total of 528 (62.5%) 
patients were treated with radiation, in the adjuvant setting. 
Hormonal agents were prescribed to 450 (53.2%) patients, 
tamoxifen was the most commonly prescribed drug (n = 357, 
79.3%), anastrozole, letrozole and exemestane were prescribed 
to 54, 38 and one patients respectively. Most of the 
patients (n = 273, 60.6%) are/were taking their hormonal 
therapy actively until the date of last follow-up, 71 (15.7%) 
have completed their 5 years of hormonal treatment, while 
remaining patients were switched to other hormonal agent or 
chemotherapy due to relapse, progressive disease, complication, 
intolerance, to extended aromitase inhibitors, or as switched 
therapy after 2-3 years of tamoxifen.
Relapse patterns and survival
All patients were followed at regular intervals in clinics, 
until the time of death or until they lost to follow-up with 
median follow-up of 29 months (range 1-224 months).
135 (135/728 = 18.5%) patients experienced relapse (local, 
loco-regional or distant). Distant recurrence was documented 
in 69 (9.5%) while 22 (3.0%) had a local recurrence. 
Bone, lungs and brain were the main sites of relapse. 
Most of the patients were treated with chemotherapy 
or radiotherapy while some patients were treated with 
combination treatment [Table 5]. Of all patients treated for 
relapsed disease, 32 progressed, 12 had a partial response, 
5 had minimal response and 4 had stable disease while 1 
had a complete response. 11 patients were treated after 
complete surgical removal of their relapsed disease and were 
in remission until the last follow-up.
Median RFS was 34 months while 5 year RFS was 19%. 
Hormone receptor status P = 0.05), Her2/neu (P	≤	0.01),	
tumor size (clinical or pathological [P ≤	 0.01]),	
clinical node status (P = 0.002), clinical stage at 
presentation (P	 ≤	 0.01),	 number	 of	 involved	 nodes	 on	
pathological examination (P = 0.02), administration of 
neo-adjuvant and adjuvant chemotherapy, radiotherapy and 
hormonal	 therapy	 (P	≤	 0.01	 for	 each)	 were	 significant	
contributory factors for RFS.
At the time of last follow-up (July 31, 2010), 159 (18.8%) 
patients have died due to disease, 26 (3.1%) to causes 
not related to disease or treatment, 3 (0.4%) because of 
treatment related toxicity. Median OS for all patients was 
157 months with 5 year OS of 75%, while it was 100%, 
88% and 58% for Stages I, II and III respectively. Median 
survival for Stage IV patients was 18 months [Figure 1].
Stage at presentation (P	≤	0.01),	 clinical	 and	 pathological	
tumor size (P	 ≤	 0.01),	 clinical	 and	 pathological	 node	
status (P	≤	0.01),	 tumor	grade	 (P	≤	0.01),	 lymphovascular	
invasion (P = 0.001), ER status (P = 0.02), radiation 
therapy	 (P	≤	0.01)	 and	hormonal	 therapy	 (P	≤	0.01)	were	
significant factors for OS on univariate analysis.
Clinical stage at presentation (P	≤	0.01),	 pathological	 nodal	
status (P	≤	 0.01),	 ER	 status	 (P	≤	 0.01)	were	 significant	
predictive factor for OS on multivariate analysis.
Discussion
The outcomes from breast cancer depend on multiple 
factors. Breast cancer biology including clinical stage, 
pathological subtype, hormonal and Her2/neu status are 
major contributors. Personal factors such as age, body 
mass index and race are also important. Socioeconomic 
factors, such as, access to the health-care, ability to afford 
appropriate treatment and facilities for screening and 
long-term follow-up and management are much less 
addressed.[6]Table 3: Receptor status for all patients
Receptor status n (%)
Estrogen receptor positive 436 (51.6)
Estrogen receptor negative 364 (43.1)
Estrogen receptor N/A 45 (5.3)
Progesterone receptor positive 372 (44)
Progesterone receptor negative 418 (49.5)
Progesterone N/A 54 (6.4)
Her2/neu status (by IHC)
Her2/neu 3+ 111 (13.1)
Her2/neu 2+ 148 (17.5)
Her2/neu negative/not done 586 (69.3)
Her2/neu status (by FISH)
Her2/neu positive 38 (4.5)
Her2/neu negative 93 (11)
Her2/neu not done 40 (4.7)
N/A=Not available; IHC=Immunohistochemistry; FISH=Fluorescent in situ 
hybridization Figure 1: Overall survival for all patients according to stage
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A comprehensive 10-year data is presented from Southern 
Pakistan. The data focuses on most common aspects of 
concern in breast cancer. The series reveal a younger mean 
age at presentation, i.e., 48 years as compared to 61 years 
reported in the surveillance epidemiology and end results 
(SEER) data.[7] Our data conform to the data from Karachi 
cancer registry, a population based registry representing a 
sample population from all parts of Pakistan, which showed 
that more than 60% of breast cancer patients were below 
50 years[8] and other studies reported form the country and 
surprisingly the age at presentation has remained almost same 
in last few decades.[9-11] The age distribution curve is also 
similar to the data from most neighboring countries, including 
those from Arabian peninsula[12] and the east Asia.[13] A small 
number of patients (9.9%) presented with Stage I disease, 
while nearly half (48.5%) had Stage II disease, which seems 
to be similar with SEER data; where 60% of patients are 
diagnosed to have the localized disease, but differs widely in 
advanced stage disease as 5% patients had Stage IV disease 
at presentation in SEER data as compared to 14.1% in our 
study. This highlights the changes in the trends perhaps set by 
screening programs and early stage detection.[14,15] A diagnosis 
at an early stage is a strong negative predictor of recurrence 
and therefore improves the long-term survival.[9,16]
The number of patients presenting with Stage IV disease 
in our study were more than double compared with the 
western literature (14% vs. 5%). Even for patients with 
non-metastatic disease a significant number had advanced 
tumor size (T4 lesions). Once staged our patients did not 
show vastly different pattern in terms of number and size 
of the lymph nodes involved and with the mean number of 
lymph nodes involved when compared with data presented 
by Carter et al.[17] In comparison to contemporary data 
the hormone receptor status was found to be lower in our 
population with over half of all patient’s tumors expressed 
ER, whereas, 44% expressed PR receptors.
Most of our patients underwent MRM, with trends for breast 
conserving surgery relatively underutilized in most clinical 
situations which reflects the same trend in other institutions 
offering breast cancer surgery in the country.[11,18] A high success 
rate for sentinel lymph node biopsy has been previously reported 
from our institute already.[19]
Neo-adjuvant chemotherapy was effectively utilized in almost 
three quarters of patients with locally advanced disease. 
A combination of adriamysin and cyclophohomide (AC) was 
the most commonly used chemotherapy regimen. Less than 
3.6% of the patient received epirubicin. The reasons remain 
speculative; however, slightly higher unit cost compared to 
doxorubicin may have contributed. Not all patients could afford 
taxane based chemotherapy. Close to 24% managed to get a 
taxane combination when it was required either in the adjuvant 
or in the metastatic setting. Trastuzumab is now considered 
as an integral part of management regimen in Her2/neu over 
expressing breast cancers. A majority of our patients however 
could not afford to take adjuvant trastuzumab and in fact a very 
few actually received the drug for 1 year in the adjuvant setting. 
Financial difficulties leading to inability to receive standard 
adjuvant treatment affects the OS in developing countries, or 
where there is a lack of widespread health insurance system. 
Tamoxifen was the most favored hormonal agent prescribed. 
Regardless of the menopausal status, a trend which is consistent 
with practice observed by physicians world-wide and reported 
by us previously.[20] Our patients showed a 3% over all 
incidence of local relapse compared to international report of 
5% as reported in National Surgical Adjuvant Breast and Bowel 
Project NSABP-04 for adequately treated patient, with matching 
figures for distant recurrences as well.[21] In our data series on a 
10 year follow-up breast cancer, survival rates match the survival 
rates reported internationally and regionally [Figure 1].[21,22]
The data presented has limitations, including a possible 
inherent bias of being from a single institution; it 
Table 4: Chemotherapy regimes
Intent/chemotherapy regimen No. (%)
Neo-adjuvant chemotherapy
AC 106 (12.5)
FAC/FEC 31 (3.6)
TAC 27 (3.2)
Taxane (paclitaxel or docetaxel) 
after anthracycline
72 (8.5)
Trastuzumab* 8 (0.9)
Hormonal treatment 8 (0.9)
TCH 3 (0.4)
Adjuvant chemotherapy
AC  109 (12.8)
FAC/FEC 184 (21.7)
AC/FAC→paclitaxel 
(3 weekly/dose dense/weekly)
100 (11.8)
TAC 20 (2.3)
CMF 32 (3.7)
AC/FAC→docetaxel 5 (0.5)
Taxane (paclitaxel or docetaxel) 
(after anthracycline)
42 (4.9)
Trastuzumab (with or after taxane) 39 (4.6)
A=Doxorubicin; C=Cyclophosphamide; E=Epirubicin; F=Fluorouracil; 
H=Trastuzumab; M=Methotrexate; T=Docetaxel; *With or without taxane
Table 5: Relapse patterns of patients
Relapse patterns (n=728) 
No. (%)
Site of relapse
Distant relapse 69 (9.5)
Local relapse 22 (3.0)
Contra lateral relapse 16 (2.2)
Loco-regional relapse 9 (1.2)
Loco-regional and distant relapse 13 (1.8)
Contra lateral and distant relapse 2 (0.2)
Relapse while on adjuvant chemotherapy 4 (0.6)
Site of first distant relapse
Bone 17 (12.59)
Lungs 14 (10.37)
Brain 13 (9.62)
Liver 6 (4.4)
Pleura 5 (3.7)
Bone+lung 9 (6.6)
Liver+lung+bone 6 (4.4)
Carcinomatous meningitis 3 (2.2)
Others 15 (11.1)
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nevertheless represents a significant contribution as south 
Karachi, our sample population, is considered to be the 
habitat of a population representative of the whole of the 
country of Pakistan.[23] Although the data presented here, 
may not be a complete representation of the prevailing 
trends of breast cancer in Pakistan, it however should 
contribute immensely to the existing scarce information on 
patterns and trends of the population from the subcontinent. 
The fact that the data set is perhaps the largest coming out 
from any single institution in Pakistan, makes it distinct. The 
patterns that have come to light by this study highlight the 
needs of further large scale population based studies to be 
done so that cost-effective guidelines on breast cancer care 
are made specific to the needs of this population.
Though the World Health Organization has mentioned 
about the age distribution of cancer for Pakistan and 
available cancer treatment facilities it does not mention the 
outcome at large and our data may help to establish or 
provide a platform for implementation of the guide lines for 
the breast cancer treatment in the country, but may also help 
to focus on the population screening in future.[24]
It should also be noted that our institution plays key role in 
cancer registry through its wide laboratory network across 
the country through, which large number of pathology 
specimen are sent to the pathology laboratory, which help 
to assess the cancer burden in the country.[4]
Conclusion
In conclusion, this data set presented from a 10 years 
follow-up of breast cancer patients at our institute suggests 
that breast cancer appears at relatively younger age and 
relatively advanced stage of the disease. The pathologic 
and biologic parameters show some distinct patterns from 
the region. Treatment modalities offered are according to 
the internationally accepted standards, but affordability 
and availability of the same remains restricted for most 
population. Despite these factors an overall trend of 
matching survival are found in comparison to regional and 
international data with regards to survival, however further 
large scale studies and comparative analysis are needed to 
improve the assessment of epidemiological and survival 
trends of our population.
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